Claims
- 1. A compound of Formula I wherein:X is O or S; Y is H or alkyl of 1 to 10 carbon atoms; R1 is H, alkyl of 1 to 10 carbon atoms, —CH2-cycloalkyl of 3 to 10 carbon atoms, —CH2-bicycloalkyl of 7 to 10 carbon atoms, m is an integer of 0 to 4; R2 is H or alkyl of 1 to 10 carbon atoms; R3 is H, halogen, alkyl of 1 to 10 carbon atoms, —O-alkyl of 1 to 10 carbon atoms or hydroxy; Z is O, S, or —CH2—; Or R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula: n is an integer of 1 or 2; R7 and R8 are independently selected from H, halogen, alkyl of 1 to 10 carbon atoms, -0-alkyl of 1 to 10 carbon atoms and hydroxy; R4 and R5 are independently hydrogen, alkyl of 1 to 10 carbon atoms, —O-alkyl of 1 to 10 carbon atoms, —S-alkyl of 1 to 10 carbon atoms, —CN, —NO2, or halogen; or a pharmaceutically acceptable salt thereof.
- 2. A compound of claim 1 in which R1 is —(CH2)mZ—R; m is 0, Z is —CH2— and R is selected from the group consisting of: or a pharmaceutically acceptable salt thereof.
- 3. The compound of claim 1 which is 8-(benzylamino-methyl)-3,5,7,8-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]naphthalen-2-one or a pharmaceutically acceptable salt thereof.
- 4. A pharmaceutical composition comprising a compound of Formula (I): wherein:X is O or S; Y is H or alkyl of 1 to 10 carbon atoms; R1 is H, alkyl of 1 to 10 carbon atoms, —CH2-cycloalkyl of 3 to 10 carbon atoms, —CH2-bicycloalkyl of 7 to 10 carbon atoms, m is an integer of 0 to 4; R2 is H or alkyl of 1 to 10 carbon atoms; R3 is H, halogen, alkyl of 1 to 10 carbon atoms, —O-alkyl of 1 to 10 carbon atoms or hydroxy; Z is O, S, or —CH2—; or R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula: n is an integer of 1 or 2; R7 and R8 are independently selected from H, halogen, alkyl of 1 to 10 carbon atoms, -0-alkyl of 1 to 10 carbon atoms and hydroxy; R4 and R5 are independently hydrogen, alkyl of 1 to 10 carbon atoms, —O-alkyl of 1 to 10 carbon atoms, —S-alkyl of 1 to 10 carbon atoms, —CN, —NO2, or halogen; or a pharmaceutically acceptable salt thereof.
- 5. A method for treating diseases of brain dopamine dysregulation, which comprises administering to a subject in need thereof an effective amount of a compound of Formula I wherein:X is O or S; Y is H or alkyl of 1 to 10 carbon atoms; R1 is H, alkyl of 1 to 10 carbon atoms, —CH2-cycloalkyl of 3 to 10 carbon atoms, —CH2-bicycloalkyl of 7 to 10 carbon atoms, m is an integer of 0 to 4; R2 is H or alkyl of 1 to 10 carbon atoms; R3 is H, halogen, alkyl of 1 to 10 carbon atoms, -0-alkyl of 1 to 10 carbon atoms or hydroxy; Z is O, S, or —CH2—; or R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula: n is an integer of 1 or 2; R7 and R8 are independently selected from H, halogen, alkyl of 1 to 10 carbon atoms, -0-alkyl of 1 to 10 carbon atoms and hydroxy; R4 and R5 are independently hydrogen, alkyl of 1 to 10 carbon atoms, —O-alkyl of 1 to 10 carbon atoms, —S-alkyl of 1 to 10 carbon atoms, —CN, —NO2, or halogen; or a pharmaceutically acceptable salt thereof.
- 6. The method of claim 5 wherein the disease of brain dopamine dysregulation is schizophrenia, Parkinson's disease, hyperprolactinemia, depression or Tourette's syndrome.
- 7. The method of claim 6 wherein the disease of brain dopamine dysregulation is schizophrenia.
- 8. The method of claim 5 wherein the disease of brain dopamine dysregulation is alcohol or drug addiction.
Parent Case Info
This application claims priority from copending provisional application Serial No. 60/306,930, filed Jul. 20, 2001, the entire disclosure of which is hereby incorporated by reference.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
5318988 |
Schohe-hoop et al. |
Jun 1994 |
A |
5371094 |
Heine et al. |
Dec 1994 |
A |
5750556 |
Mewshaw et al. |
May 1998 |
A |
5756532 |
Stack et al. |
May 1998 |
A |
Foreign Referenced Citations (1)
Number |
Date |
Country |
0 771 801 |
Oct 1996 |
EP |
Non-Patent Literature Citations (3)
Entry |
Richard E. Mewshaw et al., Bioorg. & Med. Chem. Letters,1999, 2593-2598, 9. |
Richard E. Mewshaw et al., J. Med. Chem., 1999, 2007-2020, 42. |
Richard E. Mewshaw et al., Bioorg. & Med. Chem Letters, 2002, 271-274, 12. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/306930 |
Jul 2001 |
US |